A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Solid Tumours

Interventions

DRUG

BA1301

BA1301 is administered intravenously once every three weeks.

Trial Locations (1)

RECRUITING

Cancer Hospital Affiliated to Harbin Medical University, Harbin

All Listed Sponsors

lead

Shandong Boan Biotechnology Co., Ltd

INDUSTRY